Xiao-Yong Huang
Overview
Explore the profile of Xiao-Yong Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
2021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Liang C, Hu S, Huang X, Yu L, Meng X, et al.
J Transl Med
. 2024 Oct;
22(1):883.
PMID: 39354613
Single-cell technology depicts integrated tumor profiles including both tumor cells and tumor microenvironments, which theoretically enables more robust diagnosis than traditional diagnostic standards based on only pathology. However, the inherent...
2.
Huang X, Zhang P, Wei C, Peng R, Lu J, Gao C, et al.
Mol Cancer
. 2024 Feb;
23(1):44.
PMID: 38424621
No abstract available.
3.
Lu J, Wu L, Sun Y, Huang X, Gao C, Guo X, et al.
Nat Commun
. 2024 Jan;
15(1):621.
PMID: 38245530
Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR...
4.
Dong Z, Cai J, Shi G, Yang Y, Huang X, Zhang C, et al.
Cancer Lett
. 2023 Apr;
564:216186.
PMID: 37105392
Evading immune destruction is an emerging hallmark of cancer and a potential key step in tumorigenesis. Immune checkpoint blocker (ICB)-based combination therapies revolutionize the landscape of systemic therapy for HCC....
5.
Shi G, Huang X, Wu D, Sun H, Liang F, Ji Y, et al.
Signal Transduct Target Ther
. 2023 Mar;
8(1):106.
PMID: 36928584
Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC....
6.
Guo X, Huang X, Yang X, Lu J, Wei C, Gao C, et al.
Cell Death Dis
. 2023 Feb;
14(2):79.
PMID: 36732324
Multidrug resistance is a major challenge in treating advanced hepatocellular carcinoma (HCC). Although recent studies have reported that the multidrug resistance phenotype is associated with abnormal DNA methylation in cancer...
7.
Wei C, Zhu M, Zhang P, Huang X, Wan J, Yao X, et al.
J Hepatol
. 2022 Dec;
78(4):881-882.
PMID: 36564318
No abstract available.
8.
Meng X, Lu J, Zeng H, Chen Z, Guo X, Gao C, et al.
Hepatol Int
. 2022 Nov;
17(1):63-76.
PMID: 36418844
Background: Perineural invasion (PNI) is associated with metastasis in malignancies, including intrahepatic cholangiocarcinoma (ICC), and is correlated with poor prognosis. Methods: The study included three large cohorts: ZS-ICC and TMA...
9.
Shi G, Huang X, Wen T, Song T, Kuang M, Mou H, et al.
Cancer Med
. 2022 Sep;
12(4):4137-4146.
PMID: 36127767
Objective: This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background:...
10.
Gao C, Wang S, Lu J, Chai X, Li Y, Zhang P, et al.
Biomark Res
. 2022 Apr;
10(1):25.
PMID: 35468812
Background: Kinase suppressor of Ras 2 (KSR2) is a regulator of MAPK signaling that is overactivated in most hepatocellular carcinoma (HCC). We sought to determine the role of KSR2 in...